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Abstract An 83-year-old female began treatment with
prednisolone and ursodeoxycholic acid at 62 years of age,
following a diagnosis of primary biliary cirrhosis (PBC)
and secondary Sjo¨gren’s syndrome (SjS). With persisting
bloody stools, the patient underwent colonoscopy at
83 years of age. Histopathological evaluation revealed
mucosa-associated lymphoid tissue (MALT) lymphoma.
The elevated rectal lesion resolved with rituximab treat-
ment. We report this case because although patients with
SjS are at increased risk of malignant lymphoma, primary
rectal MALT lymphoma is very uncommon in association
with PBC and secondary SjS.
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Introduction
Optimal treatment for rectal mucosa-associated lymphoid
tissue (MALT) lymphoma, an uncommon type of lym-
phoma, has yet to be established. Recently, several cases of
complete response for MALT lymphoma have been
achieved using rituximab monotherapy as an alternative to
the conventional treatments of Helicobacter pylori eradi-
cation and surgery [1–4]. In addition, patients with
Sjo¨gren’s syndrome (SjS) show a 2.6-fold greater risk of
developing a malignancy and a 37.5-fold greater risk of
developing non-Hodgkin’s lymphoma relative to healthy
individuals [5]. Primary biliary cirrhosis (PBC) is occa-
sionally listed as a complication of SjS, but in our search of
the relevant literature, MALT lymphoma as a complication
of SjS and PBC was confined to bone marrow, lacrimal
glands, lungs, and liver [6, 7]. These cases were treated
with chemotherapy, radiation and surgery, respectively.
Along with a brief review of the literature, we report a
rare case of primary rectal MALT lymphoma responding to
rituximab monotherapy in a patient undergoing long-term
follow-up for PBC and SjS.
Case report
In 1993, a 62-year-old female was referred from her pri-
mary doctor for further evaluation for Raynaud’s symp-
toms and abnormal hepatic function. She showed positive
results for anti-mitochondrial M2 antibody (AMA-M2) at
59.8 index, and although liver biopsy revealed no evidence
of chronic non-suppurative destructive cholangitis, was
diagnosed with PBC based on histological findings of bile
duct destruction. At the same time the patient was diag-
nosed with PBC she showed negative results for anti-SS-A
and anti-SS-B antibodies, despite complaining of thirst and
eye dryness. She was examined at the Department of
Otolaryngology at our hospital and was diagnosed with SjS
secondary to PBC based on a positive Schirmer’s test result
and labial gland biopsy results. Ursodeoxycholic acid
treatment (600 mg/day) and prednisolone (PSL) treatment
(30 mg/day) were initiated. PSL was subsequently tapered
and discontinued in 2007. Ursodeoxycholic acid treatment
was continued on an outpatient basis. The patient
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underwent lower gastrointestinal tract endoscopy in
December 2013 for bloody stools. A mildly red elevated
lesion measuring 5 mm maximum diameter was found in
the rectum below the peritoneal reflection. An endoscopy
performed in May 2014 showed the rectal lesion to have
transformed to a pitted, red submucosal tumor (Fig. 1a).
The lesion appeared as normal mucosa on narrow-band
imaging colonoscopy. A hypoechoic lesion was seen in the
second to third layers on endoscopic ultrasonography
(Fig. 1b). As the histopathological examination revealed no
evidence of malignancy and infiltration of lymphoid cells,
an immunohistochemical examination was not performed.
Although the histopathological examination revealed no
fibromuscular obliteration, the patient was diagnosed with
rectal mucosal prolapse syndrome based on endoscopic
findings of similarity with lymphoma. With mild bloody
stools persisting, the patient was admitted to our depart-
ment in July 2014 for further evaluation and treatment.
Tests on admission revealed thrombocytopenia and
anemia. Liver function was classified as Child-Pugh class
B based on blood biochemistry tests. Positive serum
antinuclear antibody findings (1:640 speckled pattern) and
a high AMA-M2 (41.3 index) were not inconsistent with
PBC.
Soluble interleukin-2 receptor was slightly elevated, but
all other tumor markers were within the normal ranges.
Negative results were obtained for both anti-H. pylori
antibody and H. pylori antigen stool test.
Colonoscopy performed in July 2014 showed the rectal
lesion as a hard, reddish, elevated lesion measuring 30 mm
maximum diameter (Fig. 2). Histopathological examina-
tion of the elevated lesion and surrounding mucosa with
hematoxylin and eosin (H&E) staining showed dense
infiltration of small to medium-sized lymphocytes into the
mucosa, with some lymphocytic infiltration in the crypt
epithelium (Fig. 3a). Tissues were diffusely positive for
CD20 staining and negative for CD3 staining (Fig. 3b, c). j
light-chain staining was more pronounced than k staining
at the site. As Ki-67 (MIB-1) labeling index was 30 % and
immunohistochemistry for CD5, cyclinD1, and CD10
showed negative staining, we diagnosed MALT lymphoma
(Fig. 3d).
In contrast to abdominal computed tomography (CT)
performed in December 2013, which showed only hepatic
cirrhosis and splenomegaly, abdominal CT performed
when the patient was admitted showed ascites, thickening
of the rectal wall and evidence of surrounding inflamma-
tion, and enlargement of the lateral and para-aortic lymph
nodes. Positron emission tomography/CT revealed cir-
cumferential fluorodeoxyglucose (FDG) accumulation in
the rectum below the peritoneal reflection (Rb) and FDG
accumulation in the lateral and para-aortic lymph nodes
(Fig. 4). The lesion was classified using Lugano classifi-
cation as stage II2 malignant lymphoma based on these
findings. Duodenoscopy and CT revealed no other MALT
lymphoma within the gastrointestinal tract. The patient
refused aggressive examinations, such as enteroscopy and
surgery because the hepatic cirrhosis was uncompensated,
the prognosis for MALT lymphoma is relatively good, and




enlargement of the elevation
and a reddish depression at the
center of the lesion in the lower
rectum (Rb). b Endoscopic
ultrasonography shows the
tumor to be situated in the
second to third layers. Internal
echo is non-uniform and slightly
hypoechoic. No invasion into
the fourth layer is evident
Fig. 2 Colonoscopy performed on admission shows the rectal lesion
to have become a hard elevated lesion measuring 30 mm maximum
diameter. The surrounding mucosa is circumferentially red and
edematous from Rb to Ra
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surgery would have required colostomy. Although H.
pylori eradication has proven effective in some patients
showing negative results for the pathogen [8, 9], it was not
performed for this patient because she had PBC and SjS,
which indicated autoimmune involvement. Although upper
gastrointestinal endoscopy showed slight mucosal atrophy
in the antrum of the stomach, there was no H. pylori
infection as well as no history of H. pylori eradication.
Radiation therapy was effective for primary rectal MALT
lymphoma with no distant spread [10–12]. In this case, four
courses of once-weekly rituximab, which has a favorable
safety profile, were prescribed at 375 mg/m2 with the
consent of the patient and her family to treat persistent
bleeding. A proctoscopy performed 3 months after treat-
ment showed the elevated lesion to have flattened almost
entirely (Fig. 5). A biopsy showed only mild lymphocytic
infiltration. CT revealed reduction of rectal wall thickening
and surrounding inflammation with no lymph node
enlargement, as seen before rituximab treatment. The
efficacy of rituximab monotherapy was partial remission of
MALT lymphoma in this case. Further rituximab
monotherapy was not performed for this patient because
Fig. 3 Histopathological
examination of a colon biopsy
sample shows infiltration of
small to medium-sized
lymphocytes. a H&E staining
(magnification 4009) shows
small to medium-sized atypical
lymphocytes (centrocyte-like
cells) densely infiltrating into
the mucosa. Some lymphocytic
infiltration is seen in the crypt
epithelium (lymphoepithelial
lesion). b, c Tissues show
diffusely positive CD20 staining
(b) and negative CD3 staining
(c) (magnification 4009).
d Immunohistochemistry of Ki-
67 (MIB-1) shows the labeling
index is 30 %
Fig. 4 PET-CT and abdominal
CT show a poorly demarcated
high-absorption mass with
surrounding inflammation
measuring 65942970 mm in
Rb (c). Accumulation into and
enlargement of the para-aortic
lymph nodes and lateral lymph
nodes is apparent (a, b)
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she had no bloody stools and did not wish further
treatment.
Discussion
Gastrointestinal lymphomas occur predominantly in the
stomach (60–65 %) and small intestine (approximately
30 %). Lymphomas in the colon and rectum are rare
(B10 %) [13].
The patient, who was being followed for previously
identified PBC and SjS, developed primary rectal MALT
lymphoma with gastric mucosal atrophy on upper gas-
trointestinal endoscopy, but no H. pylori infection. SjS-
associated malignant lymphoma is thought to result when
chronic inflammation from autoimmunity causes T lym-
phocytes to release cytokines that cause B-lymphocyte
proliferation and monoclonal transformation [14]. The
resulting B-cell hyperplasia is thought to progress to
MALT lymphoma over many years, and become highly
malignant. Anywhere from 6 months to 29 years can sep-
arate SjS diagnosis from the onset of malignant lymphoma
[15]. Immune reactions in glandular tissues cause SjS,
while those in bile duct epithelial cells cause PBC [16].
Many years of lymphoid tissue immune reactions caused
by PBC and SjS, in addition to infection, may therefore
have been behind the pathogenesis of MALT lymphoma in
this case [17].
In our search of the relevant literature, MALT lym-
phoma has been reported in patients with both PBC and SjS
in only the liver, lungs, bone marrow, and lacrimal glands
[6, 7]. These cases were treated with chemotherapy, radi-
ation and surgery, respectively. Of 8 patients with primary
hepatic MALT lymphoma described in a report by Kikuma
et al., two had coexisting hepatitis C virus infection, and
four had PBC, SjS, or autoimmune hepatitis [6]. Chronic
inflammation caused by infection or persisting immune
reactions appears to contribute to MALT lymphoma
pathogenesis in patients with PBC, SjS, or other
immunological disease.
Although MALT lymphomas can occur in patients
without an autoimmune disease, we must consider the
contribution not only of infection, but also of chronic
inflammation in the body when managing rectal MALT
lymphoma in patients with an autoimmune disease because
the colon is home to countless microorganisms that con-
stantly subject it to diverse antigenic stimulations and
chemical attacks [18].
Rituximab has recently been used to treat MALT lym-
phoma resistant to eradication therapy and, as monother-
apy, has shown a response rate of 40–70 %. The response
rate of non-gastric MALT lymphomas to rituximab
monotherapy is approximately 80 % [4]. The adverse
effects associated with rituximab, such as nausea following
the initial dose, are symptomatically treatable, making the
drug relatively safe even in elderly patients. We selected
rituximab monotherapy for our patient because she showed
negative results for anti-H. pylori antibody and H. pylori
antigen in the stools, had poor hepatic function due to PBC
(Child-Pugh class B), and showed enlargement of the
abdominal lymph nodes. The rectal lesion was markedly
smaller after completing 4 courses and showed no evidence
of recurrence at 3 months post treatment.
In conclusion, the relationship between MALT lym-
phoma of the rectum and PBC with SjS is not clear,
although this case report indicates that MALT lymphoma
can be caused by various factors associated with infections
and immune reactions. Clinical results observed in our
experience confirm that the use of rituximab monotherapy
can be considered effective for inoperable patients with
MALT lymphoma with autoimmune complications.
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Fig. 5 The lesion has flattened at 3 months post treatment
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